Kraematon Investment Advisors’s Novavax NVAX Stock Holding History

Kraematon Investment Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-800	Closed	-$8.22K	–	190
2022 Q4	$8.22K	Buy	+800	New	+$14.1K	0.01%	208

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kraematon Investment Advisors's NVAX Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Novavax (NVAX) in Q1 2023, closing a stake of 800 shares — an estimated $8.22K sold.

Kraematon Investment Advisors first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $8.22K in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

Kraematon Investment Advisors reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
Kraematon Investment Advisors sold 800 Novavax shares in Q1 2023, an estimated $8.22K.
Kraematon Investment Advisors first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
Kraematon Investment Advisors's Novavax position peaked at $8.22K in Q4 2022.
222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.